Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Not yet recruiting · NCT06015568 · Registry updated 2023-08-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation | Non-Small Cell Lung Cancer、EGFR Sensitive Mutation | Not yet recruiting | Phase 1 | 2023-08-29 | NCT06015568 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Betta Pharmaceuticals Co., Ltd. | 20 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hunan Cancer Hospital | Changsha | China | 87 |
| Shanghai Chest Hospital | Shanghai | China | 56 |
| The First Affiliated Hospital of Bengbu Medical College | Bengbu | China | 15 |